Skip to content

Progress Bifurcation Global Registry

Prospective Global Registry of Percutaneous Coronary Intervention in Bifurcation Lesions (PROGRESS-BIFURCATION)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05100992
Enrollment
4000
Registered
2021-10-29
Start date
2020-04-23
Completion date
2030-01-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Coronary Bifurcation Lesions

Keywords

bifurcation lesions, percutaneous coronary intervention

Brief summary

Coronary bifurcation lesions are lesions (or blockages) that occur at or near the intersection of a major coronary artery and one of the arteries' side branches. Numerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. This study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (PCI) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation PCI, the procedural strategies utilized, and the procedural outcomes.

Detailed description

Numerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. Several techniques are currently being utilized to treat coronary bifurcation lesions, including a 1-stent provisional stenting technique. Various 2-stent techniques are also performed, including: double kiss crush (DK crush4), culotte, T and protrusion (TAP), crush, mini-crush, reverse crush and V-stenting. The optimal technique for bifurcation stenting when two stents are required remains controversial; however, the DK crush technique appears to have stronger data, especially for left main bifurcations. However, DK crush can be challenging to perform, requiring several steps and frequent troubleshooting. The adoption of DK crush and other 2-stent bifurcation strategies, as well as the rigor of implementation, have received limited study. This study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (PCI) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation PCI, the procedural strategies utilized,

Interventions

PROCEDUREPercutaneous Coronary Interbention

Percutaneous Coronary Interbention

Sponsors

Minneapolis Heart Institute Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Over 18 years of age * undergoing bifurcation percutaneous coronary intervention

Design outcomes

Primary

MeasureTime frameDescription
Procedural Success During Bifurcation PCIFrom Date of Procedure to Date of Hospital Discharge, approximately 48-72 hrs after index procedure.procedural success is defined as the absence of in-hospital major cardiac adverse events (MACE), including any of the following adverse events prior to hospital discharge: death, stroke, myocardial infarction, recurrent angina requiring urgent repeat target vessel revascularization with PCI or coronary bypass surgery, and tamponade requiring pericardiocentesis or surgery.

Secondary

MeasureTime frameDescription
Technical SuccessFrom Date of Procedure to Date of Hospital Discharge, approximately 48-72 hrs after index procedure.Technical success will be defined as successful bifurcation lesion recanalization by any method with achievement of \< 30% residual stenosis and TIMI 3 flow in both the main vessel and side branch.

Countries

United States

Contacts

CONTACTEmmanouil Brilakis, MD, PhD
emmanouil.brilakis@allina.com612-863-3852
CONTACTBavana Rangan, BDS, MPH
bavana.rangan@allina.com612-863-3852

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026